EP0572563A4 - Treatment of esophageal cancer - Google Patents

Treatment of esophageal cancer

Info

Publication number
EP0572563A4
EP0572563A4 EP19920908199 EP92908199A EP0572563A4 EP 0572563 A4 EP0572563 A4 EP 0572563A4 EP 19920908199 EP19920908199 EP 19920908199 EP 92908199 A EP92908199 A EP 92908199A EP 0572563 A4 EP0572563 A4 EP 0572563A4
Authority
EP
European Patent Office
Prior art keywords
treatment
esophageal cancer
esophageal
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19920908199
Other versions
EP0572563A1 (en
Inventor
Randall Keith Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0572563A1 publication Critical patent/EP0572563A1/en
Publication of EP0572563A4 publication Critical patent/EP0572563A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP19920908199 1991-02-21 1992-02-07 Treatment of esophageal cancer Withdrawn EP0572563A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65893691A 1991-02-21 1991-02-21
US658936 1991-02-21

Publications (2)

Publication Number Publication Date
EP0572563A1 EP0572563A1 (en) 1993-12-08
EP0572563A4 true EP0572563A4 (en) 1993-12-29

Family

ID=24643326

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920908199 Withdrawn EP0572563A4 (en) 1991-02-21 1992-02-07 Treatment of esophageal cancer

Country Status (8)

Country Link
EP (1) EP0572563A4 (en)
JP (1) JPH06505487A (en)
KR (1) KR930702985A (en)
AU (1) AU664172B2 (en)
CA (1) CA2104449A1 (en)
MX (1) MX9200725A (en)
PT (1) PT100154A (en)
WO (1) WO1992014470A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6849599B2 (en) 2000-03-08 2005-02-01 Rhode Island Hospital Combination drug therapy
CA2404431C (en) 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
US8053183B2 (en) 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
ES2371171B1 (en) * 2010-06-08 2012-11-16 Consejo Superior De Investigaciones Científicas (Csic) CAMPTOTECHINE DERIVATIVES AS ANTITUMOR AGENTS.
CN102659800B (en) * 2012-05-11 2014-09-03 中国药科大学 Hypoxia-activated antitumor compounds and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0321122A2 (en) * 1987-12-01 1989-06-21 Smithkline Beecham Corporation Water soluble camptothecin analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0321122A2 (en) * 1987-12-01 1989-06-21 Smithkline Beecham Corporation Water soluble camptothecin analogs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C.G. MOERTEL ET AL: "Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer.", CANCER CHEMOTHER REP., vol. 56, no. 1, 1972, pages 95 - 101 *
M.R. MATTERN ET AL: "Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor SKF 104864.", PROC. AM. ASSOC. CANCER RES. ANNU. MEET., vol. 31, 1990, pages 436 *
See also references of WO9214470A1 *
Y. OHE ET AL: "Pharmacokinetics with a 5-day continuous infusion of a camptothecin derivative, CPT-11.", PROC. ANNU. MEET. AM. SOC. CLIN. ONCOL., vol. 10, 1991, pages 117 *

Also Published As

Publication number Publication date
WO1992014470A1 (en) 1992-09-03
EP0572563A1 (en) 1993-12-08
CA2104449A1 (en) 1992-08-22
AU664172B2 (en) 1995-11-09
AU1540692A (en) 1992-09-15
PT100154A (en) 1993-05-31
JPH06505487A (en) 1994-06-23
MX9200725A (en) 1992-09-01
KR930702985A (en) 1993-11-29

Similar Documents

Publication Publication Date Title
GB9127150D0 (en) Novel treatment
IL103302A0 (en) Treatment of meat
GB9113971D0 (en) Treatment of water
GB9303210D0 (en) Cancer treatment
EP0448677A4 (en) Treatment of colon cancer
EP0572563A4 (en) Treatment of esophageal cancer
GB9217998D0 (en) Methods of treating cancer
GB9218711D0 (en) Skin cancer treatment
GB9117210D0 (en) Treatment of cancer
ZA923359B (en) Treatment of longitudinally extending members
GB9218713D0 (en) Gastrointestinal cancer treatment
GB9008524D0 (en) Treatment of cancer
GB9226032D0 (en) Treatment of cancer
ZA9210001B (en) Treatment of psychoses
GB9026737D0 (en) Cancer treatment
ZA899631B (en) Cancer treatment
GB8908539D0 (en) Treatment of cancer
GB2266241B (en) Treatment of pastures
GB9125670D0 (en) Treatment of neurogical conditions
EP0705104A4 (en) Method of cancer treatment
GB9124347D0 (en) Treatment of macrophages
RU1833739C (en) Way of treatment hyperekaliemia
GB9212535D0 (en) Treatment of boimass
GB9110578D0 (en) Treatment of seeds
RU1833736C (en) Means of treatment of psoriasis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19931111

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19971211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980422

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1012266

Country of ref document: HK